“Our late stage cadisegliatin program is advancing with potential to be the first oral adjunct therapy for T1D,” said Paul Sekhri, Chairman, president and CEO of vTv Therapeutics (VTVT). “We reinitiated screening in our Phase 3 CATT1 study and, based upon the recent protocol amendment to shorten the study from 12 to 6 months, we expect topline Phase 3 data for cadisegliatin in the second half of 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
- VTVT Upcoming Earnings Report: What to Expect?
- vTv Therapeutics Appoints Barry Brown as Interim CFO
- Promising Potential of vTv Therapeutics’ Cadisegliatin in Addressing Unmet Needs in Type 1 Diabetes
- vTv Therapeutics initiated with a Buy at H.C. Wainwright